DXCM

$82.972.11%-1.79

Dopo l'orario di chiusura: 82.96-0.01 -0.01%

Dexcom Inc (DXCM)

Date: O: H: L: C: Vol:

Precedente Chiudi:

$84.76

Aprire:

$84.55

Volume 24 ore:

4,117,162

Volume relativo:

0.65

Capitalizzazione di mercato:

$30.94B

Reddito:

$4.82B

Utile/perdita netta:

$930.40M

Rapporto P/E:

35.49

EPS:

$2.34

Flusso di cassa netto:

$1.43B

1W Prestazione:

+5.61%

1M Prestazione:

-2.80%

6M Prestazione:

+35.24%

1Y Prestazione:

+37.30%

Intervallo 1D:

$82.81$85.18

Intervallo di 1 settimana:

$77.69$85.25

Portata 52W:

$54.11$92.59

Profilo aziendale di Dexcom Inc (DXCM)

Nome

Dexcom Inc

Settore

Healthcare

Industria

Medical Devices

Telefono

(858) 200-0200

Indirizzo

6340 SEQUENCE DRIVE, SAN DIEGO, CA, USA

Dipendente

11,100

@dexcom

Prossima data di guadagno

null

Ultimi documenti SEC

SEC

Discussioni di DXCM su X

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Dexcom Inc Azioni (DXCM) Upgrade e downgrade

Data	Azione	Analista	Modifica della valutazione
2026-10-07	Iniziato	Barclays	Overweight
2026-06-23	Iniziato	Deutsche Bank	Buy
2026-05-12	Iniziato	The Benchmark Company	Buy
2026-03-24	Aggiornamento	Evercore ISI	In-line → Outperform
2026-01-12	Downgrade	Barclays	Equal Weight → Underweight
2025-12-02	Aggiornamento	Morgan Stanley	Equal-Weight → Overweight
2025-11-25	Iniziato	Evercore ISI	In-line
2025-10-21	Resumed	Stifel	Buy
2025-09-08	Downgrade	Oppenheimer	Outperform → Perform
2025-08-21	Iniziato	Argus	Buy
2025-06-16	Iniziato	Truist	Buy
2025-05-30	Iniziato	Goldman	Buy
2025-04-10	Iniziato	Mizuho	Outperform
2025-02-03	Aggiornamento	Redburn Atlantic	Neutral → Buy
2025-01-16	Aggiornamento	Robert W. Baird	Neutral → Outperform
2024-07-26	Downgrade	JP Morgan	Overweight → Neutral
2024-07-26	Downgrade	Robert W. Baird	Outperform → Neutral
2024-05-30	Iniziato	Redburn Atlantic	Neutral
2024-03-12	Iniziato	RBC Capital Mkts	Outperform
2023-05-30	Resumed	Morgan Stanley	Equal-Weight
2023-04-17	Aggiornamento	Raymond James	Outperform → Strong Buy
2023-03-29	Iniziato	UBS	Buy
2023-01-26	Iniziato	Wolfe Research	Outperform
2022-10-18	Iniziato	Barclays	Equal Weight
2022-10-12	Iniziato	Jefferies	Buy
2022-07-15	Iniziato	Bernstein	Outperform
2022-03-02	Resumed	BofA Securities	Buy
2022-02-03	Aggiornamento	BTIG Research	Neutral → Buy
2022-01-19	Aggiornamento	Wells Fargo	Equal Weight → Overweight
2022-01-07	Aggiornamento	Guggenheim	Neutral → Buy
2021-10-18	Downgrade	Guggenheim	Buy → Neutral
2021-07-21	Resumed	Cowen	Outperform
2021-05-28	Aggiornamento	Wells Fargo	Underweight → Equal Weight
2021-05-25	Iniziato	Barclays	Overweight
2021-04-15	Iniziato	Atlantic Equities	Overweight
2021-01-06	Aggiornamento	UBS	Neutral → Buy
2020-10-02	Downgrade	Wells Fargo	Equal Weight → Underweight
2020-05-27	Reiterato	Piper Sandler	Overweight
2020-05-14	Iniziato	Wells Fargo	Equal Weight
2020-03-05	Iniziato	Citigroup	Buy
2019-11-07	Reiterato	Canaccord Genuity	Buy
2019-11-07	Aggiornamento	Guggenheim	Neutral → Buy
2019-10-23	Iniziato	Stifel	Buy
2018-11-28	Iniziato	UBS	Neutral
2018-10-19	Aggiornamento	Goldman	Sell → Neutral
2018-09-12	Aggiornamento	Northland Capital	Under Perform → Market Perform
2018-08-02	Reiterato	Canaccord Genuity	Buy
2018-07-02	Aggiornamento	Raymond James	Mkt Perform → Outperform
2018-06-08	Aggiornamento	JP Morgan	Neutral → Overweight
2018-05-11	Iniziato	BofA/Merrill	Buy
2018-05-03	Reiterato	Canaccord Genuity	Buy
2018-04-04	Iniziato	Goldman	Sell
2018-04-04	Iniziato	Guggenheim	Neutral
2018-03-23	Aggiornamento	Robert W. Baird	Neutral → Outperform
2018-01-04	Downgrade	Northland Capital	Market Perform → Under Perform
2017-09-28	Reiterato	Wedbush	Outperform

Dexcom Inc Azioni (DXCM) Dati Finanziari

Periodo	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Data di fine periodo	2025-12-31	2024-12-31	2023-12-31	2022-12-31	2021-12-31
Revenue USD (M)	4,662.00	4,033.00	3,622.30	2,909.80	2,448.50
Cost of revenue USD (M)	1,860.10	1,594.80	1,333.40	1,026.70	768.00
Gross profit USD (M)	2,801.90	2,438.20	2,288.90	1,883.10	1,680.50
Research and development USD (M)	599.10	552.40	505.80	484.20	517.10
Operating expenses USD (M)	1,890.10	1,838.20	1,691.20	1,491.90	1,414.70
Operating income USD (M)	911.80	600.00	597.70	391.20	265.80
Income before tax USD (M)	1,088.40	709.00	710.40	390.80	173.90
Income tax expense USD (M)	252.10	132.80	168.90	49.60	19.20
Net income USD (M)	836.30	576.20	541.50	341.20	154.70
Basic EPS USD/shares	2.14	1.46	1.40	0.88	1.60
Diluted EPS USD/shares	2.09	1.42	1.30	0.82	1.55
Basic weighted shares shares (M)	390.20	393.60	386.00	389.40	96.70
Diluted weighted shares shares (M)	405.50	412.70	425.50	427.50	100.10
Selling, general and administrative USD (M)	1,291.00	1,285.80	1,185.40	1,000.20	810.50

Dexcom Inc Azioni (DXCM) insider trading

SADIE STERNOct 27 '26
Officer
Transazione
Proposed Sale
Costo
$78.62
#Azioni
2,565
Valore ($)
201,660
#Azioni Totale
0
Stern SadieOct 27 '26
EVP Chief People & Culture Off
Transazione
Sale
Costo
$78.62
#Azioni
2,565
Valore ($)
201,660
#Azioni Totale
120,913
MICHAEL BROWNOct 15 '26
Officer
Transazione
Proposed Sale
Costo
$85.48
#Azioni
1,700
Valore ($)
145,316
#Azioni Totale
0
Brown Michael JonOct 15 '26
EVP Chief Legal Compliance Off
Transazione
Sale
Costo
$85.48
#Azioni
1,700
Valore ($)
145,316
#Azioni Totale
98,185
Stern SadieSep 28 '26
EVP Chief People & Culture Off
Transazione
Sale
Costo
$86.15
#Azioni
2,565
Valore ($)
220,975
#Azioni Totale
123,478
SADIE STERNSep 28 '26
Officer
Transazione
Proposed Sale
Costo
$86.15
#Azioni
2,565
Valore ($)
220,975
#Azioni Totale
0
MICHAEL BROWNSep 15 '26
Officer
Transazione
Proposed Sale
Costo
$84.04
#Azioni
1,700
Valore ($)
142,868
#Azioni Totale
0
AUGUSTINOS NICHOLASSep 15 '26
Director
Transazione
Sale
Costo
$84.04
#Azioni
6,539
Valore ($)
549,538
#Azioni Totale
29,293
AUGUSTINOS NICHOLASSep 15 '26
Director
Transazione
Proposed Sale
Costo
$84.04
#Azioni
6,539
Valore ($)
549,538
#Azioni Totale
0
Brown Michael JonSep 15 '26
EVP Chief Legal Compliance Off
Transazione
Sale
Costo
$84.04
#Azioni
1,700
Valore ($)
142,868
#Azioni Totale
99,885

Commercio interno	Relazione	Data	Transazione	Costo	#Azioni	Valore ($)	#Azioni Totale
SADIE STERN	Officer	Oct 27 '26	Proposed Sale	$78.62	2,565	201,660	0
Stern Sadie	EVP Chief People & Culture Off	Oct 27 '26	Sale	$78.62	2,565	201,660	120,913
MICHAEL BROWN	Officer	Oct 15 '26	Proposed Sale	$85.48	1,700	145,316	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Oct 15 '26	Sale	$85.48	1,700	145,316	98,185
Stern Sadie	EVP Chief People & Culture Off	Sep 28 '26	Sale	$86.15	2,565	220,975	123,478
SADIE STERN	Officer	Sep 28 '26	Proposed Sale	$86.15	2,565	220,975	0
MICHAEL BROWN	Officer	Sep 15 '26	Proposed Sale	$84.04	1,700	142,868	0
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Sale	$84.04	6,539	549,538	29,293
AUGUSTINOS NICHOLAS	Director	Sep 15 '26	Proposed Sale	$84.04	6,539	549,538	0
Brown Michael Jon	EVP Chief Legal Compliance Off	Sep 15 '26	Sale	$84.04	1,700	142,868	99,885

Dexcom Inc Borsa (DXCM) Ultime notizie

10:59 AM

DexCom to Launch 15-Day G7 CGM System in Canada This November - Zacks Investment Research

10:59 AM

02:30 AM

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence - GlobeNewswire Inc.

02:30 AM

Nov 02, 2026

Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion - MedTech Dive

Nov 02, 2026

More than 589 million people worldwide live with diabetes. Nick Jonas shares his story in Dexcom's letter campaign. - Stock Titan

Nov 02, 2026

DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:DXCM) 2026-11-02 - Seeking Alpha

Nov 02, 2026

Nov 01, 2026

DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM) - Seeking Alpha

Nov 01, 2026

Oct 31, 2026

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory - Yahoo Finance

Oct 31, 2026

Oct 30, 2026

DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says - Yahoo Finance

Oct 30, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

Oct 30, 2026

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

Oct 30, 2026

DexCom Inc Reports Q3 2026 Earnings: EPS of $0.72 and Revenue of $1.344 Billion Exceed Estimates - GuruFocus

Oct 29, 2026

DexCom: Q3 Earnings Snapshot - Yahoo Finance

Oct 29, 2026

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Oct 29, 2026

Earnings Flash (DXCM) DexCom, Inc. Reports Q3 Revenue $1.34B, vs. FactSet Est of $1.33B - marketscreener.com

Oct 29, 2026

Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67 - marketscreener.com

Oct 29, 2026

Oct 28, 2026

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Oct 28, 2026

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Oct 28, 2026

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Oct 28, 2026

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

Oct 28, 2026

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Oct 28, 2026

Oct 27, 2026

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Oct 27, 2026

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Oct 27, 2026

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Oct 27, 2026

Oct 26, 2026

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

Oct 26, 2026

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Oct 26, 2026

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Oct 26, 2026

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Oct 26, 2026

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

Oct 26, 2026

Oct 24, 2026

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

Oct 24, 2026

Oct 23, 2026

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Oct 23, 2026

Oct 21, 2026

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

Oct 21, 2026

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Oct 21, 2026

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

Oct 21, 2026

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

Oct 21, 2026

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

Oct 21, 2026

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Oct 21, 2026

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

Oct 21, 2026

Oct 20, 2026

DexCom Inc. Company & People | DXCM.USD - Barron's

Oct 20, 2026

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

Oct 20, 2026

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Oct 20, 2026

Oct 19, 2026

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Oct 19, 2026

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Oct 19, 2026

Oct 18, 2026

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

Oct 18, 2026

Simile a DXCM

Dexcom Inc (DXCM)

Profilo aziendale di Dexcom Inc (DXCM)

Cap. di mercato

Reddito

Reddito netto

Flusso di cassa

EPS

Dexcom Inc Azioni (DXCM) Upgrade e downgrade

Dexcom Inc Azioni (DXCM) Dati Finanziari

Dexcom Inc Azioni (DXCM) insider trading

Dexcom Inc Borsa (DXCM) Ultime notizie

DexCom to Launch 15-Day G7 CGM System in Canada This November - Zacks Investment Research

Continuous Glucose Monitoring Market in India: USD 452.9 Million Opportunity by 2032 as Digital Diabetes Care Expands, Reports Mordor Intelligence - GlobeNewswire Inc.

Abbott, Dexcom grapple with diabetes coverage ahead of planned Medicare expansion - MedTech Dive

More than 589 million people worldwide live with diabetes. Nick Jonas shares his story in Dexcom's letter campaign. - Stock Titan

DexCom, Inc. 2026 Q3 - Results - Earnings Call Presentation (NASDAQ:DXCM) 2026-11-02 - Seeking Alpha

DexCom: Improving Patient Access Makes It A Long-Term Buy (NASDAQ:DXCM) - Seeking Alpha

DXCM Q3 deep dive: clinical momentum and new product launches support growth trajectory - Yahoo Finance

DexCom Q3 Results, Higher Revenue Guidance Point to Stronger 2027, RBC Says - Yahoo Finance

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Zacks Investment Research

DexCom Stock Up on Q3 Earnings & Revenue Beat, Margins Rise - Yahoo Finance

DexCom Inc (DXCM) Q3 2026 Earnings Call Highlights: Double-Digit - GuruFocus

What DexCom (DXCM) Said on Its Q3 Earnings Call - TradingView

Why is DexCom stock climbing today? - Investing.com

DexCom Inc Reports Q3 2026 Earnings: EPS of $0.72 and Revenue of $1.344 Billion Exceed Estimates - GuruFocus

DexCom: Q3 Earnings Snapshot - Yahoo Finance

DexCom (DXCM) Surpasses Q3 Earnings and Revenue Estimates - Yahoo Finance

Earnings Flash (DXCM) DexCom, Inc. Reports Q3 Revenue $1.34B, vs. FactSet Est of $1.33B - marketscreener.com

Earnings Flash (DXCM) DexCom, Inc. Posts Q3 Adjusted EPS $0.73 per Share, vs. FactSet Est of $0.67 - marketscreener.com

DexCom (DXCM) to Launch Dexcom G7 15 Day CGM System in Canada Ne - GuruFocus

Dexcom launches 15-day glucose monitor in Canada next month By Investing.com - Investing.com India

Dexcom G7 15 Day Continuous Glucose Monitoring System to Launch in Canada in November - DexCom, Inc. - Investor Relations

Dexcom G7 15 Day glucose monitor to launch in Canada in November - StreetInsider

What to expect from DexCom’s (DXCM) Q3 earnings - Yahoo Finance

Here’s How Much You Would Have Made Owning DexCom Stock In The Last 15 Years - Benzinga

Our Dexcom Pick Had a Minor Setback. It’s Still a Diabetes Winner. - Barron's

Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire

Is DexCom (DXCM) Cheap After CONNECT Trial Results Backed G7 Adoption? - Simply Wall Street

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - Zacks Investment Research

DexCom Gears Up to Report Q3 Results: How to Play the Stock? - TradingView

Leerink Partners Adjusts Price Target on DexCom to $87 From $94 - marketscreener.com

Dexcom Inc Lobbying Profile, 2020 - OpenSecrets

Form 144 DEXCOM For: 26 October By Investing.com - Investing.com Nigeria

DexCom, Inc. (DXCM) Options Chain - Yahoo Finance - Yahoo! Finance Canada

DexCom, Inc. Estimates – NASDAQ:DXCM - TradingView

Why Is DexCom (DXCM) In Focus After Its G7 Trial Reached NEJM? - Yahoo Finance

DexCom Inc (DXCM) Shares Fall 6.4% -- What GF Score of 95 Tells Investors - GuruFocus

Precision Trading with Dexcom Inc. (DXCM) Risk Zones - Stock Traders Daily

DexCom Inc. stock underperforms Wednesday when compared to competitors - MarketWatch

DexCom (DXCM) Shares Fall 6.5% Amid Broader Market Gains on Octo - GuruFocus

S&P 500 Top Movers on Oct. 21, 2026: Supermicro Leads Gainers, Dexcom Leads Losers - ChartMill

Global Digital Health and Remote Patient Monitoring Strategic Market Report, 2026-2031 | 20.2% CAGR to $80.8 Billion as Connected Care and Wearables Scale - GlobeNewswire Inc.

DexCom Inc. Company & People | DXCM.USD - Barron's

DXCM.USD | DexCom Inc. Stock Overview (Switzerland: SWX) - Barron's

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Zacks Investment Research

DexCom's G7 Shows Strong Results in Type 2 Diabetes CONNECT Study - Yahoo! Finance Canada

Form 4 DexCom Inc: Michael Jon Brown (EVP Chief Legal Compliance Off) For: 15 October By Investing.com - Investing.com South Africa

Dexcom EVP Michael Brown sells $145,316 in company stock - Investing.com

Dexcom class action lawsuits claim ShinyHunters stole health data - Top Class Actions

Simile a DXCM